GlaxoSmithKline's new boss streamlines drug research
[LONDON] GlaxoSmithKline's new chief executive Emma Walmsley announced plans on Wednesday to streamline drug research in a bid to improve returns in the group's core pharmaceuticals business.
Ms Walmsley, who took over in April, said GSK would allocate capital to priority areas including respiratory and HIV and infectious diseases, and two potential areas of oncology and immuno-inflammation. More than 30 pre-clinical and clinical programmes will be stopped.
The announcement came as Britain's biggest drugmaker reported a 12 per cent rise in adjusted earnings per share in sterling terms to 27.2 pence on sales up 12 per cent at £7.32 billion (S$12.97 billion). Analysts, on average, had forecast sales of £7.26 billion and EPS of 26.2 pence, according to Thomson Reuters data.
REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Coca-Cola raises annual organic sales forecast on global demand, higher prices
Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too
Billionaire Geiger is said to near US$7 billion L’Occitane buyout
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder